The Cost-Effectiveness of Counseling Strategies to Improve Adherence to Highly Active Antiretroviral Therapy among Men Who Have Sex with Men
暂无分享,去创建一个
[1] J. Leonard,et al. Decrease of HIV‐1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine , 1998, AIDS.
[2] Milton C Weinstein,et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. , 2003, The American journal of medicine.
[3] B. Roca,et al. Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. , 1999, The Journal of infection.
[4] Blair T. Johnson,et al. Efficacy of Antiretroviral Therapy Adherence Interventions: A Research Synthesis of Trials, 1996 to 2004 , 2006, Journal of acquired immune deficiency syndromes.
[5] J. Kahn,et al. Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.
[6] E. Vittinghoff,et al. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. , 1997, American journal of epidemiology.
[7] J. Schapiro,et al. Economic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV‐Infected Patients in the VIRADAPT Study , 2000, Journal of acquired immune deficiency syndromes.
[8] L. Rodrigues,et al. Heterosexual transmission of HIV. , 1992, BMJ.
[9] M. Otto,et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. , 2001, Behaviour research and therapy.
[10] Julio S. G. Montaner,et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long‐term response to therapy , 1998, AIDS.
[11] G. Peytavin,et al. Relationship between Levels of Indinavir in Hair and Virologic Response to Highly Active Antiretroviral Therapy , 2002, Annals of Internal Medicine.
[12] T. Coates,et al. Maintenance of safer sexual behaviors and predictors of risky sex: the San Francisco Men's Health Study. , 1990, American journal of public health.
[13] D. Cooper,et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV‐1‐infected individuals , 1998, AIDS.
[14] A. Mocroft,et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. , 2000, Archives of internal medicine.
[15] G. Godin,et al. Efficacy of interventions in improving adherence to antiretroviral therapy , 2005, International journal of STD & AIDS.
[16] R. Royce,et al. Sexual transmission of HIV. , 1997, The New England journal of medicine.
[17] H. Günthard,et al. Effect of Individual Cognitive Behaviour Intervention on Adherence to Antiretroviral Therapy: Prospective Randomized Trial , 2004, Antiviral therapy.
[18] Milton C Weinstein,et al. The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States , 2006, Medical care.
[19] V. Robison,et al. Male Viral Load and Heterosexual Transmission of HIV‐1 Subtype E in Northern Thailand , 2002, Journal of acquired immune deficiency syndromes.
[20] A. Egberts,et al. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[21] F. Hecht,et al. Quantitative and Cost Comparison of Ultrasensitive Human Immunodeficiency Virus Type 1 RNA Viral Load Assays: Bayer bDNA Quantiplex Versions 3.0 and 2.0 and Roche PCR Amplicor Monitor Version 1.5 , 2000, Journal of Clinical Microbiology.
[22] D. Vlahov,et al. A PROSPECTIVE STUDY OF ADHERENCE AND VIRAL LOAD IN A LARGE MULTI-CENTER COHORT OF HIV-INFECTED WOMEN , 2002, AIDS.
[23] John W. Mellors,et al. Panel on Clinical Practices for Treatment of HIV Infection , 2000 .
[24] H. Gershengorn,et al. A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.
[25] Richard A. Loftus,et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.
[26] I. de Vincenzi,et al. Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. European Study Group in Heterosexual Transmission of HIV. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[27] Joel Tsevat,et al. The Will To Live among HIV-Infected Patients , 1999, Annals of Internal Medicine.
[28] A. Guerrero,et al. Risk factors for ritonavir intolerance and outcome after change to indinavir. , 1998, AIDS.
[29] F. Maggiolo,et al. Simpler Regimens May Enhance Adherence to Antiretrovirals in HIV-Infected Patients , 2002, HIV clinical trials.
[31] A. Mocroft,et al. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor , 1998, AIDS.
[32] L. Pollack,et al. Bringing HIV/STI testing programmes to high-risk men. , 2005, International journal of STD & AIDS.
[33] J. Parsons,et al. Integration of motivational interviewing and cognitive behavioral therapy to improve HIV medication adherence and reduce substance use among HIV-positive men and women: results of a pilot project. , 2005, AIDS patient care and STDs.
[34] T. Heeren,et al. Unsafe sex in men who have sex with both men and women. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[35] J L Sullivan,et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1996, The New England journal of medicine.
[36] Douglas K Owens,et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. , 2005, The New England journal of medicine.
[37] R. Hogg,et al. Determinants of sexual risk-taking among young HIV-negative gay and bisexual men. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[38] Amalio Telenti,et al. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) , 1998, The Lancet.
[39] W. Heneine,et al. Low prevalence of antiretroviral resistance among persons recently infected with human immunodeficiency virus in two US cities , 2002, International journal of STD & AIDS.
[40] Richard D Moore,et al. Hepatitis C and progression of HIV disease. , 2002, JAMA.
[41] S. Weller,et al. The effectiveness of condoms in reducing heterosexual transmission of HIV. , 1999, Family planning perspectives.
[42] M. Egger,et al. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. , 2000, Archives of internal medicine.
[43] P. Domingo,et al. Switching HIV-1 protease inhibitor therapy: which? When? And why? , 1999, Archives of internal medicine.
[44] D. Richman,et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. , 1998, JAMA.
[45] E A Emini,et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.
[46] Donald A. Redelmeier,et al. Economic methods for measuring the quality of life associated with HIV infection , 1999, Quality of Life Research.
[47] J. Alcamí,et al. Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. , 1999, Journal of acquired immune deficiency syndromes.
[48] R Rode,et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. , 1999, AIDS.
[49] C. Quereda,et al. Effectiveness and Pitfalls of Initial Highly Active Antiretroviral Therapy in HIV-Infected Patients in Routine Clinical Practice , 1999, Antiviral therapy.
[50] R. Pollard. Can HIV infection be treated successfully with a once-daily regimen? , 2002, The AIDS reader.
[51] V. Diehl,et al. Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study. , 1999, European journal of medical research.
[52] R. Chaisson,et al. Adherence to Nonnucleoside Reverse Transcriptase InhibitorBased HIV Therapy and Virologic Outcomes , 2007, Annals of Internal Medicine.
[53] R. Hogg,et al. The antiviral effect of ritonavir and saquinavir incombination amongst HIV‐infected adults: results from a community‐based study , 1998, AIDS.
[54] J. Montaner,et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.
[55] Margaret L. Brandeau,et al. The Effects of Protease Inhibitors on the Spread of HIV and the Development of Drug-Resistant HIV Strains: A Simulation Study , 1998, Simul..
[56] M. Opravil,et al. The SPICE Study: 48‐Week Activity of Combinations of Saquinavir Soft Gelatin and Nelfinavir With and Without Nucleoside Analogues , 2000, Journal of acquired immune deficiency syndromes.
[57] D. Katzenstein,et al. Rapid Communication: Efavirenz‐ and Adefovir Dipivoxil‐Based Salvage Therapy in Highly Treatment‐Experienced Patients: Clinical and Genotypic Predictors of Virologic Response , 2000, Journal of acquired immune deficiency syndromes.
[58] Robert Shafer,et al. HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed , 1999, Annals of Internal Medicine.
[59] D A Revicki,et al. Change in clinical status, health status, and health utility outcomes in HIV-infected patients. , 1995, Medical care.
[60] Are nelfinavir-containing regimens effective as second-line triple therapy? , 2000, AIDS.
[61] H. Gershengorn,et al. Predicting the unpredictable: Transmission of drug-resistant HIV , 2001, Nature Medicine.
[62] Douglas K Owens,et al. Screening Women of Childbearing Age for Human Immunodeficiency Virus: A Model-Based Policy Analysis , 1993 .
[63] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[64] B. Yip,et al. Antiviral effect of double and triple drug combinations amongst HIV‐infected adults: lessons from the implementation of viral load‐driven antiretroviral therapy , 1998, AIDS.
[65] M L Brandeau,et al. HIV transmission and the cost-effectiveness of methadone maintenance. , 2000, American journal of public health.
[66] J. Casado,et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study , 2002, AIDS.
[67] R. D. Webster,et al. HIV testing among men who have sex with men: how often should one test? , 2005, Journal of public health management and practice : JPHMP.
[68] J. Bartlett,et al. Highly active antiretroviral therapy and sexual risk behavior: A metaanalytic review , 2004 .
[69] A. Hurley,et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals , 2002, AIDS.
[70] D. Haas,et al. Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[71] B. Turner. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. , 2002, The Journal of infectious diseases.
[72] B. Boyle. Editorial comment: once-daily antiretroviral therapy. , 2002, The AIDS reader.
[73] R. Hays,et al. A Comparison Study of Multiple Measures of Adherence to HIV Protease Inhibitors , 2001, Annals of Internal Medicine.
[74] Joseph Quinn,et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults , 2006, AIDS.
[75] S. Vermund,et al. Adherence to HAART among HIV-infected persons in rural Louisiana. , 2004, AIDS patient care and STDs.
[76] T. Coates,et al. Actual versus perceived HIV status, sexual behaviors and predictors of unprotected sex among young gay and bisexual men who identify as HIV‐negative, HIV‐positive and untested , 1997, AIDS.
[77] S. Ra,et al. High-risk sexual behavior and condom use among gay and bisexual men. , 1993 .
[78] A. Wu,et al. Interventions to Improve Adherence to Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.
[79] A. Carballo-Diéguez,et al. Couple-focused support to improve HIV medication adherence: a randomized controlled trial , 2005, AIDS.
[80] B. Roca,et al. A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients , 2000, AIDS.
[81] U. C. Bureau. Statistical Abstract of the United States , 2004 .
[82] J. Gallant,et al. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. , 1999, AIDS.
[83] A. Sönnerborg,et al. Persistence of earlier HIV‐1 drug resistance mutations at new treatment failure , 2002, Journal of medical virology.
[84] M. Saag,et al. Predictors of optimal virological response to potent antiretroviral therapy. , 1999, AIDS.
[85] J. Goedert,et al. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. The Multicenter Hemophilia Cohort Study. , 2000, The Journal of infectious diseases.
[86] T. Coates,et al. High HIV risk-taking among young gay men. , 1990, AIDS.
[87] M. Lederman,et al. Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. , 1999, Archives of internal medicine.
[88] M. Moroni,et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral‐experienced patients in advanced stages of HIV‐1 infection , 1998, AIDS.
[89] Edward H. Kaplan. Asymptotic worst-case mixing in simple demographic models of HIV/AIDS. , 1992, Mathematical biosciences.
[90] G. Marks,et al. Prevalence of high-risk sex among HIV-positive gay and bisexual men: a longitudinal analysis. , 1996, American journal of preventive medicine.
[91] F. Parazzini,et al. Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study , 2000, Journal of acquired immune deficiency syndromes.
[92] T. Coates,et al. Unprotected sex and HIV risk taking among young gay men within boyfriend relationships. , 1997, AIDS education and prevention : official publication of the International Society for AIDS Education.
[93] C. Boucher,et al. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). , 1999, AIDS.
[94] H. Gershengorn,et al. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? , 2002, The Lancet. Infectious diseases.
[95] J. Ward,et al. Statistical analysis of the stages of HIV infection using a Markov model. , 1989, Statistics in medicine.
[96] K. Tashima,et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.
[97] Adeeba Kamarulzaman,et al. AIDS Res Hum Retroviruses , 2006 .
[98] T. Merigan,et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .
[99] D K Owens,et al. Screening women of childbearing age for human immunodeficiency virus. A cost-benefit analysis. , 1992, Archives of internal medicine.
[100] Atlanta,et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[101] Susan Swindells,et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[102] R. Chaisson,et al. Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.
[103] P. Barton,et al. Antidepressant Treatment Improves Adherence to Antiretroviral Therapy Among Depressed HIV-Infected Patients , 2005, Journal of acquired immune deficiency syndromes.
[104] F. Hecht,et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.
[105] A. Telenti,et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.
[106] Richard D Moore,et al. Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? , 2002, AIDS patient care and STDs.
[107] M C Weinstein,et al. Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. , 1996, Medical care.
[108] I. de Vincenzi,et al. A Longitudinal Study of Human Immunodeficiency Virus Transmission by Heterosexual Partners , 1994 .
[109] D. McCaffrey,et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. , 2001, The New England journal of medicine.
[110] P. Bellman. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed , 1998, AIDS.
[111] B. Ledergerber,et al. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. , 1999, AIDS research and human retroviruses.
[112] K. Kabeya,et al. Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine. , 1999, AIDS.
[113] P. Duong,et al. Virologic response associated with a change in protease inhibitor therapy. , 2000, Archives of internal medicine.
[114] Prabhat Jha,et al. Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. , 2002, Bulletin of the World Health Organization.
[115] Elaine R Reynolds,et al. Adherence to antiretroviral therapy in HIV-infected pediatric patients improves with home-based intensive nursing intervention. , 2004, AIDS patient care and STDs.
[116] C. Rietmeijer,et al. HIV serostatus disclosure among gay and bisexual men in four American cities: general patterns and relation to sexual practices. , 1998, AIDS care.
[117] E. Kohli,et al. Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[118] C Inch,et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. , 2006, The Cochrane database of systematic reviews.
[119] C. Quereda,et al. Predictors of long‐term response to protease inhibitor therapy in a cohort of HIV‐infected patients , 1998, AIDS.
[120] R. Hogg,et al. HIV infection and risk behaviours among young gay and bisexual men in Vancouver. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[121] C. Castillo-Chavez. Mathematical and Statistical Approaches to Aids Epidemiology , 1989 .
[122] R. Paredes,et al. High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. , 1999, Journal of acquired immune deficiency syndromes.
[123] N. Jewell,et al. Female-to-male transmission of human immunodeficiency virus. , 1992, JAMA.
[124] W. Mcfarland,et al. Very Young Gay and Bisexual Men Are at Risk for HIV Infection: The San Francisco Bay Area Young Men's Survey II , 2000, Journal of acquired immune deficiency syndromes.
[125] Mark Dybul,et al. Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV* , 2002, Annals of Internal Medicine.
[126] B. Leynaert,et al. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. , 1998, American journal of epidemiology.
[127] R. Rohrsheim,et al. Clinical audit: adherence to sexually transmitted infection screening guidelines for men who have sex with men. , 2005, International journal of STD & AIDS.
[128] A. Phillips,et al. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era , 2003, AIDS.
[129] Melissa R. Pfeiffer,et al. Estimation of HIV Prevalence, Risk Factors, and Testing Frequency among Sexually Active Men Who Have Sex with Men, Aged 18–64 Years—New York City, 2002 , 2007, Journal of Urban Health.
[130] L. Kalish,et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. , 1999, The New England journal of medicine.
[131] D. Watts,et al. Small Worlds: The Dynamics of Networks between Order and Randomness , 2001 .
[132] P. Vernazza,et al. Probability of heterosexual transmission of HIV. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[133] L. Osterberg,et al. Adherence to medication. , 2005, The New England journal of medicine.
[134] R. Gelber,et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.
[135] B. Turner,et al. Antiretroviral adherence interventions: a review of current literature and ongoing studies. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[136] W Winkelstein,et al. Male-to-female transmission of human immunodeficiency virus. , 1987, JAMA.
[137] P. Jatlow,et al. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. , 2002, The American journal on addictions.
[138] T. Quinn,et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.
[139] P. Bonfanti,et al. Virological treatment failure of highly active antiretroviral therapy in an unselected cohort of HIV-infected patients. , 1998, AIDS.
[140] C. Hoff,et al. HIV risk among Latino gay men in the Southwestern United States. , 1996, AIDS education and prevention : official publication of the International Society for AIDS Education.
[141] J. Montaner,et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.
[142] J. Catania,et al. High-risk sexual behavior and condom use among gay and bisexual African-American men. , 1992, American journal of public health.
[143] J. Rockstroh,et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV‐infected patients , 1997, AIDS.
[144] O. Kirk,et al. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. , 1999, AIDS.
[145] T. Coates,et al. Gay men report high rates of unprotected anal sex with partners of unknown or discordant HIV status. , 1999, AIDS.
[146] L. Eldred,et al. The cost of HIV medication adherence support interventions: Results of a cross-site evaluation , 2005, AIDS care.
[147] S. Kippax,et al. In a minority of gay men, sexual risk practice indicates strategic positioning for perceived risk reduction rather than unbridled sex , 2002, AIDS care.
[148] R. Janssen,et al. HIV incidence among young men who have sex with men--seven U.S. cities, 1994-2000. , 2001, MMWR. Morbidity and mortality weekly report.
[149] D. Bangsberg,et al. Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[150] David Madigan,et al. Implementation Brief: A Two-way Messaging System to Enhance Antiretroviral Adherence , 2003, J. Am. Medical Informatics Assoc..
[151] J. Elvira,et al. Effect of Patient Adherence to Antiretroviral Therapy on CD4+ Cell Count, HIV-1 RNA, and Serum Concentrations of Tumor Necrosis Factor and its Soluble Receptors , 2000, European Journal of Clinical Microbiology and Infectious Diseases.
[152] W. Bilker,et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load , 2001, AIDS.
[153] J. Dilley,et al. Psychosocial correlates of unprotected anal sex in a cohort of gay men attending an HIV-negative support group. , 1998, AIDS education and prevention : official publication of the International Society for AIDS Education.
[154] R. Sperling. Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant. , 1997 .
[155] I. de Vincenzi. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. , 1994, The New England journal of medicine.
[156] David R. Holtgrave,et al. Estimating the cost of unmet HIV-prevention needs in the United States. , 2002, American journal of preventive medicine.
[157] H. Gershengorn,et al. Predicting the unpredictable: Transmission of drug-resistant HIV , 2003, Nature Medicine.
[158] J. Elford,et al. Sexual risk behaviour among gay men in a relationship. , 1999, AIDS.
[159] J. Schapiro,et al. Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.
[160] M A Fischl,et al. Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .
[161] V. Stone,et al. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[162] Edward H. Kaplan,et al. Nonrandom mixing models of HIV transmission , 1989 .
[163] M. Fletcher,et al. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an Urban Veterans Affairs Medical Center. , 1999, Journal of acquired immune deficiency syndromes.